GRI Bio, Inc. — 2023 Form 10-K Summary
Business context and reporting period
This is an annual report for the fiscal year ended December 31, 2023, not a standalone fourth-quarter report. GRI Bio is a clinical-stage biopharmaceutical company with no approved products and no significant product revenue. Its lead candidate, GRI-0621, is in development for idiopathic pulmonary fibrosis (IPF); GRI-0803 is a preclinical candidate initially aimed at systemic lupus erythematosus. The April 2023 merger with Vallon Pharmaceuticals was accounted for as a reverse recapitalization, with GRI Operations treated as the accounting acquirer.
Financial performance and position
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | No significant operating revenue | No significant operating revenue |
| Research and development expense | $3.232 million | $0.242 million |
| General and administrative expense | $8.155 million | $1.997 million |
| Total operating expenses | $11.387 million | $2.239 million |
| Net loss | $13.037 million | $3.217 million |
| Net loss per share, basic and diluted | $28.25 | $24.95 |
| Cash used in operating activities | $8.990 million | $1.085 million |
| Cash and cash equivalents at year-end | $1.808 million | $9,000 |
| Total assets / total liabilities | $2.956 million / $2.697 million | $0.383 million / $2.008 million |
| Stockholders’ equity (deficit) | $0.259 million | $(1.625) million |
The loss increase reflected higher development spending and, especially, merger and public-company costs. Research and development expense rose by $2.990 million, primarily for GRI-0621 development, personnel and consulting; general and administrative expense rose by $6.158 million, largely due to merger, professional and public-company costs. Net interest expense was $2.082 million, versus $0.653 million in 2022. A $0.250 million payment from the ADAIR asset sale was recorded as other income. No profit or operating margin is meaningful given the absence of product revenue.
Financing provided $10.797 million of net cash in 2023, including proceeds from the pre-merger equity financing and bridge-note funding, partly offset by transaction and issuance costs. Year-end cash included $1.224 million in uninsured bank balances. The company reported no material off-balance-sheet arrangements. The year-end balance sheet showed a $3,000 warrant liability and no remaining bridge promissory note balance; verify the terms and status of outstanding warrants and other financing securities.
Material changes and developments
- GRI commenced enrollment in a randomized, placebo-controlled Phase 2a IPF study of GRI-0621 in December 2023. The planned study covers approximately 36 patients, with topline results expected in the second half of 2024.
- The pilot Phase 2a liver-disease study of GRI-0621 stopped after 14 of a planned 60 patients because of recruitment challenges and updated FDA guidance. The filing reports tolerability and exploratory biomarker/liver-test observations, but emphasizes that the study was underpowered for statistically significant endpoints.
- GRI planned to submit an IND for GRI-0803 in the first half of 2024, subject to toxicology and regulatory progress. The filing anticipated Phase 1 results later in 2024; these are forward-looking expectations, not reported outcomes.
- In August 2023, GRI sold its ADAIR license, related patents and files to Aardvark Therapeutics for $0.250 million upfront and may receive contingent milestones. Management did not expect near-term milestone receipts.
- After year-end, GRI effected a one-for-seven reverse stock split on January 29, 2024. On February 1, 2024, it agreed to a securities offering with gross proceeds of $5.5 million, involving common stock and pre-funded and common warrants. These are subsequent events, not 2023 operating results; warrant exercises may create substantial dilution.
Outlook, liquidity, risks and unusual items
Management stated that year-end cash and cash equivalents were expected to fund operating and capital requirements only into the second half of 2024, and that additional funding would be needed to continue development. The independent auditor’s report includes a going-concern explanatory paragraph, citing recurring losses and a net capital deficiency that raise substantial doubt about the company’s ability to continue as a going concern. The filing says the February 2024 offering proceeds were insufficient to restore Nasdaq stockholders’ equity compliance, so further financing was needed.
- Nasdaq listing: GRI had a stockholders’ equity deficiency and a separate bid-price deficiency. Nasdaq required evidence of equity compliance by May 2024; the filing warns that failure to demonstrate compliance could result in delisting. The January reverse split did not ensure continued bid-price compliance.
- Clinical and development risk: GRI-0621 and GRI-0803 remain investigational. Clinical outcomes, enrollment, FDA requirements and timelines are uncertain; the prior liver study’s recruitment difficulties highlight enrollment risk.
- Funding and dilution: The company expects continuing losses and has no product revenue. Additional capital may be unavailable or costly, and equity or warrant financing can dilute existing holders. Failure to raise funds could force program reductions or cessation of operations.
- Operational reliance: GRI relies on third parties for clinical trials and manufacturing, including limited or single suppliers. Supply interruptions, quality issues or vendor delays could disrupt development.
- Other considerations: The company cites competition, regulatory and reimbursement uncertainty, intellectual-property risks, cybersecurity threats, and dependence on a small workforce. It reported no material cybersecurity incidents in the prior three fiscal years and no material pending legal proceedings.
As an unusual accounting item, the reverse merger generated substantial transaction costs; the company also recognized a $0.182 million decrease in the fair value of warrant liability in 2023. The statements reflect reverse stock splits retroactively. Management reported effective disclosure controls and internal control over financial reporting as of December 31, 2023; the auditor did not provide an internal-control attestation because of the company’s emerging-growth-company exemption.
Key facts investors should verify
- Current cash, cash runway and financing needs after the February 2024 offering, including subsequent warrant exercises and any additional capital raised.
- Whether GRI has regained Nasdaq stockholders’ equity and minimum-bid-price compliance, and the status of any delisting notices or extensions.
- Actual enrollment, safety findings and final results for the GRI-0621 IPF Phase 2a trial, and whether its timing or design has changed.
- Whether the GRI-0803 IND was submitted and cleared, and whether planned clinical-trial milestones remain achievable.
- The fully diluted share count and potential dilution from pre-funded warrants, common warrants, legacy warrants and equity-plan awards.
- Any Aardvark milestone payments, debt or warrant changes, or other subsequent events that materially affect liquidity or obligations.